A virally encoded, high-affinity Fc receptor (FcR) is found on herpes simplex virus type 1 (HSV-1) particles and infected cells where its binding of non-immune IgG protects cells from hostmediated lysis. Whilst mutation or aglycosylation of the IgG CH2 domain reduced binding to human FcR, the interaction with HSV-1 FcR was not affected. However, the HSV-1 FcR, unlike human FcR, discriminates between human IgGl allotypes, being sensitive to changes at positions 214 (CHI) and 356/358 (CH3), away from its proposed binding site at the CH2-CH3 interface. T h e biological consequences are not known but this is the first evidence of a major functional difference between IgGl allotypes.
The herpes simplex virus type I (HSV-I) Fc receptor (FcR)
FcRs are found in widely divergent human herpes viruses [1] [2] [3] [4] , and other human pathogens possess IgG-binding proteins, such as staphylococcal Protein A [5] , suggesting an important role for pathogen FcR in disease. An FcR for IgG is expressed on the HSV-1 virion envelope and on the surface of infected cells [6-91. A 1 : 1 complex of two glycoproteins, gE and gI, encoded in the HSV-1 genome, is responsible for the high-affinity binding of IgG [10, 11] . Mutants lacking an FcR have not been isolated from patients [12] , suggesting that it confers a significant selective advantage in vivo. However, it is not clear how the viral FcR functions in evading immune attack. In vitro studies have shown that aggregated nonimmune IgG bound HSV-1 FcR on infected cells, protecting them from lysis mediated by either sensitized lymphocytes or complement and specific antibody [13] . Non-immune IgG or purified Fc fragments were found to protect HSV-2 virions [17, 18, 22] and other, as yet unidentified, residues may account for binding differences between IgG molecules. We aimed to use our collections of variant human IgG to pinpoint regions involved in binding to HSV-1 FcR and to contrast these with residues important for activity via classical human FcR.
The antibody reagents and assay systems
Our laboratory has made several series of antibodies with identical variable domains and alternative constant domains. In the antibodies discussed here, the variable regions used gave specificity to the red blood cell (RBC) antigen RhD (Fog-1 variable regions [23] T h e second region involves residues 327-331 from a bend joining two P-strands at the N-terminal end of the domain. T h e Aa mutation of IgGl and IgG2 molecules introduces IgG4 residues at positions 327, 330 and 331. For IgG1, the mutations were made separately and in combination, namely GlAab and GlAac.
Interactions with HSV-1 FcR were determined by measuring the binding of antibodies to COS-7 cells which had been infected with the virus SCgHZ, a disabled mutant of HSV-1 strain SC16, to achieve a single round of infection [31] . Single cell suspensions were made in dilutions of the test antibodies and bound antibody detected using FITC-conjugated goat anti-human IgG, Fc-specific antibodies. Mean fluorescence intensities were determined by flow cytometry. Binding to the human FcR was measured using transfectants which expressed single receptors [28, . T h e binding to FcyRI (a receptor specific for the Fc region of IgG) was measured using biotinylated anti-human K-chain antibodies and avidin-FITC as detection reagents. T o overcome the low affinity of FcyRII and FcyRIII, the test antibodies were complexed with F(ab'), fragments of goat antibodies recognizing human K-chains, prior to incubating with the receptorbearing cells. Bound antibodies were detected using FITC-conjugated donkey anti-goat IgG antibodies. T h e response of monocytes to RBC sensitized with antibodies from the Fog-1 series can be used as a functional assay of FcyRI activity. The results agreed with the binding data, and Fog-1 antibodies which did not bind to FcyRI were able to block monocyte triggering due to Fog-1 I g G l . Furthermore, one of the variant antibodies, Fog-l G2Aa, was similarly shown to inhibit the response to clinically significant anti-RhD antibody in human sera.
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Interactions of the CH2 mutants with FcyRIIa of the 131R and 131H allotypes and with the inhibitory receptor FcyRIIb are also summarized in Table 1 . Both of the mutated regions had an effect on binding to FcyRII, with the lower hinge mutations (Ab and Ac) causing the largest reductions. We identified IgGl variants which react with the activating receptor, FcyRIIa, at least 10-fold less efficiently than wild-type IgGl but retain a higher level of binding to the inhibitory FcyRIIb.
104-foid.
When binding of these antibodies to FcyRIIIb was measured, the NA1 and NA2 allotypes of the receptor gave very similar profiles for the antibodies (Table 1) . Binding of IgGl was reduced 20-fold by the Aa mutation, 100-fold by Ac and about 500-fold to background levels by Ab and double mutation of IgGl. These observations are consistent with the crystal structure for a human IgGl Fc fragment-FcyRIII complex [36] , where the receptor binds across both CH2 domains of the Fc, contacting both areas mutated here. For one of the heavy chains, the loop containing residues 327-332 makes multiple contacts. The lower hinge regions of both chains interact with the receptor but in different conformations.
Natural killer cell ADCC activity against Fog-1 -sensitized RBC has been demonstrated to be FcyRI 11-mediated through the use of blocking anti-FcR antibodies. IgGl was the only consistently active wild-type antibody. IgG2 and IgG4 gave killing only with some donors and at levels at least 104-fold lower than IgGl. The Aa mutation to IgGl reduced activity by about 100-fold whereas Ac and Ab mutations effected lo4-and 105-fold reductions respectively. Double mutants of IgGl and the mutants of IgG2 and IgG4 had background levels of activity in all assays. The double mutants of IgGl and IgG4 mutants were most efficient at inhibiting ADCC of RBC, promoted by wild-type IgGl and by polyclonal antiRhD antibodies, such that lysis was reduced by 90 yo when the mutants were present in a 30-fold excess relative to I g G l .
We have shown that the sites of the Aa and Ab/Ac mutations are important in the interactions of IgG with human FcR and, as Table 1 shows, the mutations can also eliminate the ability of the IgG to activate complement. These results support our efforts to produce an inert Fc for use in any therapeutic antibody or Fc fusion protein where destruction of target cells is undesirable. One of the Fog-1 mutant antibodies is currently being tested in RBC survival studies in volunteers.
Since binding of IgG to human FcyR depended heavily on the two mutated regions, we measured the ability of these IgG mutants to bind HSV-1-infected cells (Figure la) . T h e Ab and Ac mutations did not significantly affect the binding of IgG to HSV-1 FcR, implying that amino acids 233-236 in IgG are not important in the interaction. The Aa mutation appears to increase the binding of IgG2 to the HSV-1 FcR but had no impact on the binding of I g G l . The Aa mutation introduces residues of the higher binding IgG4 and therefore it is interesting that it increases the binding of IgG2, but not to IgG4 levels. The binding specificity of the HSV-1 FcR must be determined, at least in part, by variations in the structure of IgG at positions other than those modified in the IgG CH2 mutants.
Effects of IgG I glycosylation on binding
FcyRI bound equally well to IgGl molecules of the naturally occurring allotypes Glm(l,17) and Glm(3) but, as expected, did not bind aglycosyl forms of these antibodies [29] . Aglycosylation of an IgGl antibody of allotype Glm(1,17) reduced its interaction with FcyRIIa by approx. 8-fold, with FcyRIIbl by 16-fold and eliminated binding to FcyRIIIb. The HSV-1 FcR binds both Glm(1,17) and its aglycosyl mutant to a similar extent and the same is true for Glm(3) ( Table 2 ) . This suggests that glycosylation of IgG does not have a role in HSV-1 FcR binding, contrasting with its effect on binding to classical human FcR. However, the striking discovery from these data was that the affinity of the HSV-1 FcR for Glm(3) is rela- Table 2 The 
Effects of allotypic residues on binding
We went on to determine the contributions of allotypic residues to HSV-1 FcR binding [31] . All results are summarized in Table 2 . Initially, IgGl of the artificial allotype Glm(nul1) was compared with the naturally occurring IgGl allotypes. T h e G1 m(nul1) antibody showed the same ability to bind HSV-1 -infected cells as the G1 m( 1, 17) molecule, from which it differs at all three allotypic positions. In contrast, the single mutation Thr-214 to Arg, which converts Glm(nul1) to Glm(3), significantly reduces binding. (17) and Glm(1,3) with Glm(3), we investigated the importance of residues 356 and 358. In both cases, possession of the allotypic marker G l m ( l ) , and thus the residues Asp-356 and Leu-358, promotes higher binding to the receptor than seen for antibodies with Glu-356 and Met-358.
Biological consequences
The HSV-1 FcR can be estimated to have a Kd of 1200 nM for the Glm(1,17) allotype of IgGl and a Ka of around 60 nM for IgG4. At normal human serum concentrations of IgGl (40-50 pM) and IgG4 (2-4 pM) [37] , HSV-1 FcR on infected cells would be saturated with antibody. In HSV-1-infected individuals with the IgGl allotype Glm(1,17), about half of the viral FcR expressed on infected cells will be occupied by nonimmune I g G l , whereas in infected individuals with the IgGl allotype Glm(3) the majority of antibodies bound to cell-surface HSV-1 FcR will be IgG4. IgGl is generally more cytotoxic than IgG4 [29] but, as the role of the viral FcR in pathogenesis is not known, the significance of the proportion of IgGl binding the HSV-1 FcR is unclear.
The IgGl allotypic variants we tested for HSV-1 FcR binding differ by no more than three residues and yet show a very broad range of interaction affinities with the HSV-1 FcR. Hence, the IgGl allotypic residues have a significant part to play in the interaction of IgGl with the viral FcR. Previous investigations have focused on the CH2-CH3 domain interface of IgG as the site of interaction with HSV-1 FcR [17, 22] . However, our results identify IgG allotypic residues at the hinge end of the CH1 domain and in the CH3 domain, away from the CH2-CH3 interface, as influencing binding to the viral receptor. The HSV-1 FcR may either have two binding sites on IgG or a large area of contact with the IgG molecule. This work is the first to identify a major functional consequence for G l m allotypes occurring naturally in the human population.
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